Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

HPV DNA vaccine shows therapeutic potential in patients with cervical intraepithelial neoplasia 3

25 Apr 2020

The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Seventy-two CIN3 patients positive for HPV type 16/18 were randomized to receive to receive GX-188E at either 1 or 4 mg. Treatment was administered intramuscularly at weeks 0, 4 and 12. Histopathologic regression to ≤CIN1 was assessed at week 20, as well as at week 36 in an extension study. Researchers performed HPV-sequencing analysis and an ex vivo IFNγ ELISpot assay using the collected cervical biopsy and blood samples from patients.

Of the patients, 64 patients were included in per-protocol analysis and 52 in extension analysis. Histopathologic regression with GX-188E overall occurred in 33 patients (52 percent) at week 20 and in 35 patients (67 percent) at week 36.

Furthermore, HPV clearance was achieved by 73 percent and 77 percent of patients with histologic regression at weeks 20 and 36, respectively. HPV clearance was significantly associated with histopathologic regression at both time points.

Patients with HPV clearance at week 36 exhibited significantly greater changes in their IFNγ ELISpot responses relative to those without HPV clearance. The HPV type 16 E6/E7 variants D25E, V83L and N29S had an inverse association with histopathologic regression at week 36.

More studies are needed to evaluate the therapeutic effect of the GX-188E vs placebo against HPV type 16/18–associated CIN3, as well as to examine the potential of tailoring HPV therapeutic vaccine according to individual HPV variants, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.